Pharming Group NV
NASDAQ:PHAR

Watchlist Manager
Pharming Group NV Logo
Pharming Group NV
NASDAQ:PHAR
Watchlist
Price: 17.89 USD 4.13% Market Closed
Market Cap: 1.2B USD
Section:
 

Relative Value

The Relative Value of one PHAR stock under the Base Case scenario is hidden USD. Compared to the current market price of 17.89 USD, Pharming Group NV is hidden .

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

PHAR Relative Value
HIDDEN
Show
Worst Case
Base Case
Best Case

Valuation Multiples

3.4
P/S
P/S
Price to Sales
3.4
vs History
25
vs Industry
77
Median 3Y
2.9
Median 5Y
2.4
Industry
8
Forward
3.3
More Details
3 204.2
P/E
P/E
Price to Earnings
3 204.2
vs History
0
vs Industry
3
Median 3Y
-42.5
Median 5Y
11.8
Industry
23.5
Forward
73.8
More Details
23.1
P/OCF
P/OCF
Price to OCF
23.1
vs History
19
vs Industry
6
Median 3Y
-33.6
Median 5Y
12.4
Industry
21.9
More Details
25.2
P/FCFE
P/FCFE
Price to FCFE
25.2
vs History
23
vs Industry
3
Median 3Y
-14
Median 5Y
12.4
Industry
24.3
More Details
4.6
P/B
P/B
Price to Book Value
4.6
vs History
6
vs Industry
34
Median 3Y
3.6
Median 5Y
3.6
Industry
3.2
More Details
3.3
EV/S
EV/S
Enterprise Value to Sales
3.3
vs History
23
vs Industry
69
Median 3Y
2.8
Median 5Y
2.3
Industry
8.1
Forward
3.2
More Details
3.6
EV/GP
EV/GP
Enterprise Value to Gross Profit
3.6
vs History
23
vs Industry
70
Median 3Y
3.1
Median 5Y
2.5
Industry
10.1
More Details
22.7
EV/EBITDA
EV/EBITDA
Enterprise Value to EBITDA
22.7
vs History
30
vs Industry
2
Median 3Y
23.9
Median 5Y
12.3
Industry
5.9
Forward
47.6
More Details
32.5
EV/EBIT
EV/EBIT
Enterprise Value to EBIT
32.5
vs History
17
vs Industry
2
Median 3Y
-24.6
Median 5Y
11.3
Industry
6.2
Forward
64.3
More Details
22.2
EV/OCF
EV/OCF
Enterprise Value to OCF
22.2
vs History
19
vs Industry
5
Median 3Y
-32
Median 5Y
12.1
Industry
7.7
More Details
22.5
EV/FCFF
EV/FCFF
Enterprise Value to FCFF
22.5
vs History
31
vs Industry
4
Median 3Y
-38.2
Median 5Y
14.5
Industry
6.3
More Details
5.2
EV/IC
EV/IC
Enterprise Value to IC
5.2
vs History
3
vs Industry
38
Median 3Y
4
Median 5Y
4.1
Industry
5.6
More Details

Multiples Across Competitors

PHAR Competitors Multiples
Pharming Group NV Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
NL
Pharming Group NV
NASDAQ:PHAR
1.1B USD 3.4 3 204.2 22.7 32.5
IL
Can Fite Biopharma Ltd
TASE:CANF
707T ILS 255 120 668.6 -17 520 045.9 -17 192 530.1 -17 154 260
FR
Pharnext SCA
OTC:PNEXF
6T USD 34 036 074.3 -161 768.4 -196 438.5 -194 196.9
US
Abbvie Inc
NYSE:ABBV
390.6B USD 6.5 166.4 16.2 22.9
US
Amgen Inc
NASDAQ:AMGN
177.3B USD 4.9 25.2 18.2 18.2
US
Gilead Sciences Inc
NASDAQ:GILD
150.3B USD 5.2 18.5 12.4 12.4
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
119.9B USD 10.2 32.6 24 25.1
US
Epizyme Inc
F:EPE
94.1B EUR 2 069.8 -528.2 -575.1 -559.8
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
84.1B USD 5.9 18.4 17.6 19.9
AU
CSL Ltd
ASX:CSL
84.4B AUD 3.6 18.8 12.7 15.8
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
53.6B USD 16.7 1 229.6 165.8 201.1
P/S Multiple
Revenue Growth P/S to Growth
NL
Pharming Group NV
NASDAQ:PHAR
Average P/S: 26 287 169.9
3.4
11%
0.3
IL
C
Can Fite Biopharma Ltd
TASE:CANF
255 120 668.6
140%
1 822 290.5
FR
Pharnext SCA
OTC:PNEXF
34 036 074.3
N/A N/A
US
Abbvie Inc
NYSE:ABBV
6.5
9%
0.7
US
Amgen Inc
NASDAQ:AMGN
4.9
5%
1
US
Gilead Sciences Inc
NASDAQ:GILD
5.2
4%
1.3
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
10.2
10%
1
US
E
Epizyme Inc
F:EPE
2 069.8
N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
5.9
6%
1
AU
CSL Ltd
ASX:CSL
3.6
5%
0.7
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
16.7
46%
0.4
P/E Multiple
Earnings Growth PEG
NL
Pharming Group NV
NASDAQ:PHAR
Average P/E: 589.2
3 204.2
N/A N/A
IL
C
Can Fite Biopharma Ltd
TASE:CANF
Negative Multiple: -17 520 045.9 N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -161 768.4 N/A N/A
US
Abbvie Inc
NYSE:ABBV
166.4
89%
1.9
US
Amgen Inc
NASDAQ:AMGN
25.2
45%
0.6
US
Gilead Sciences Inc
NASDAQ:GILD
18.5
190%
0.1
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
32.6
N/A N/A
US
E
Epizyme Inc
F:EPE
Negative Multiple: -528.2 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
18.4
10%
1.8
AU
CSL Ltd
ASX:CSL
18.8
11%
1.7
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
1 229.6
N/A N/A
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
NL
Pharming Group NV
NASDAQ:PHAR
Average EV/EBITDA: 36.2
22.7
51%
0.4
IL
C
Can Fite Biopharma Ltd
TASE:CANF
Negative Multiple: -17 192 530.1 N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -196 438.5 N/A N/A
US
Abbvie Inc
NYSE:ABBV
16.2
14%
1.2
US
Amgen Inc
NASDAQ:AMGN
18.2
11%
1.7
US
Gilead Sciences Inc
NASDAQ:GILD
12.4
7%
1.8
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
24
16%
1.5
US
E
Epizyme Inc
F:EPE
Negative Multiple: -575.1 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
17.6
11%
1.6
AU
CSL Ltd
ASX:CSL
12.7
8%
1.6
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
165.8
N/A N/A
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
NL
Pharming Group NV
NASDAQ:PHAR
Average EV/EBIT: 43.5
32.5
N/A N/A
IL
C
Can Fite Biopharma Ltd
TASE:CANF
Negative Multiple: -17 154 260 N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -194 196.9 N/A N/A
US
Abbvie Inc
NYSE:ABBV
22.9
30%
0.8
US
Amgen Inc
NASDAQ:AMGN
18.2
20%
0.9
US
Gilead Sciences Inc
NASDAQ:GILD
12.4
12%
1
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
25.1
16%
1.6
US
E
Epizyme Inc
F:EPE
Negative Multiple: -559.8 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
19.9
13%
1.5
AU
CSL Ltd
ASX:CSL
15.8
11%
1.4
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
201.1
N/A N/A

See Also

Summary
PHAR intrinsic value, competitors valuation, and company profile.
DCF Valuation
PHAR stock valuation using Discount Cash Flow valuation method.
Relative Valuation
PHAR stock valuation using valuation multiples.
Wall Street Estimates
PHAR price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
PHAR stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Back to Top
ALPHA SPREAD
Follow us
Join more than 308,500+ value investors using Alpha Spread
Create Free Account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2026 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.